FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022046439> ?p ?o ?g. }

• W2022046439 endingPage "28" @default.
• W2022046439 startingPage "21" @default.
• W2022046439 abstract "Exosomes (EXOs) derived from tumor cells have been used to stimulate antitumor immune responses. It has been demonstrated that EXO released by tumor cells engineered to express cytokines are of enhanced stimulatory effect on CD8+ cytotoxic T-lymphocyte (CTL) responses and antitumor immunity. J558 is a mouse myeloma cell line expressing tumor antigen P1A. In this study, we purified EXOTNF-a, EXOIL-2, and EXOIFN-γ released by three cytokine-gene (TNF-α, IL-2 and IFN-γ)-engineered J558 (J558TNF-a, J558IL-2 and J558IFN-γ) tumor cell lines from their culture supernatants, respectively, by differential ultracentrifugation. These EXOs showed a “saucer” or round shape with a diameter between 50 and 90 nm by electron microscopy and contained EXO-associated proteins, such as LAMP-1 and AIP1, but not lysate-associated protein galectin, by Western blot analysis. EXO displayed expression of molecules (H-2Kd, CD54, and P1A) similarly to, but to a lesser extent to, J558 tumor cells. We then compared the stimulatory effect of these EXOs on P1A-specific CD8+ CTL responses and antitumor immunity 6 days subsequent to intravenous (i.v.) EXO immunization (30 μg/each BALB/c mouse). We demonstrated that EXOTNF-α immunization was able to induce more efficient P1A-specific CD8+ T-cell response accounting for 0.62% of the total CD8+ T-cell population, using PE-H-2Kd/P1A peptide and FITC-CD8 staining by flow cytometric analysis then EXOIL-2 (0.31%) and EXOIFN-γ (0.22%) immunization (P < 0.05), respectively, at day 6 after immunization. EXOIL-2 and EXOIFN-γ vaccine (i.v. 30 μg/each mouse) only protected 3 of 8 (38%) and 2 of 8 (25%) mice from tumor growth after subcutaneous (s.c.) challenging of immunized mice with J558 tumor cells (0.5 × 106 cells/each mouse), whereas EXOTNF-α immunization protected all 8 of 8 (100%) mice from tumor growth (P < 0.05). Taken together, we demonstrate that EXOTNF-a released by engineered J558TNF-a tumor cells more efficiently stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity than EXOIL-2 and EXOIFN-γ released by engineered J558IL-2 and J558IFN-γ tumor cells. Therefore, TNF-α-expressing tumor cell-released EXO may represent a more effective EXO-based vaccine in the induction of antitumor immunity." @default.
• W2022046439 created "2016-06-24" @default.
• W2022046439 creator A5000432967 @default.
• W2022046439 creator A5051036701 @default.
• W2022046439 creator A5063363406 @default.
• W2022046439 creator A5071965865 @default.
• W2022046439 creator A5080553382 @default.
• W2022046439 date "2010-02-01" @default.
• W2022046439 modified "2023-09-22" @default.
• W2022046439 title "Tumor Necrosis Factor Gene-Engineered J558 Tumor Cell–Released Exosomes Stimulate Tumor Antigen P1A-Specific CD8⁺CTL Responses and Antitumor Immunity" @default.
• W2022046439 cites W1483777297 @default.
• W2022046439 cites W1505627520 @default.
• W2022046439 cites W1542448731 @default.
• W2022046439 cites W1600015917 @default.
• W2022046439 cites W1725537921 @default.
• W2022046439 cites W1762620449 @default.
• W2022046439 cites W1838162521 @default.
• W2022046439 cites W1889489351 @default.
• W2022046439 cites W1965913620 @default.
• W2022046439 cites W1971235178 @default.
• W2022046439 cites W1973071182 @default.
• W2022046439 cites W1977613047 @default.
• W2022046439 cites W1986321004 @default.
• W2022046439 cites W2003411005 @default.
• W2022046439 cites W2013603806 @default.
• W2022046439 cites W2028248159 @default.
• W2022046439 cites W2041302454 @default.
• W2022046439 cites W2044896831 @default.
• W2022046439 cites W2045606151 @default.
• W2022046439 cites W2055090334 @default.
• W2022046439 cites W2058404073 @default.
• W2022046439 cites W2079766756 @default.
• W2022046439 cites W2082252887 @default.
• W2022046439 cites W2085862646 @default.
• W2022046439 cites W2093400957 @default.
• W2022046439 cites W2098375525 @default.
• W2022046439 cites W2102508255 @default.
• W2022046439 cites W2113207547 @default.
• W2022046439 cites W2116842394 @default.
• W2022046439 cites W2122635106 @default.
• W2022046439 cites W2123688428 @default.
• W2022046439 cites W2141003137 @default.
• W2022046439 cites W2141346620 @default.
• W2022046439 cites W2156275638 @default.
• W2022046439 cites W2159175710 @default.
• W2022046439 cites W2161932019 @default.
• W2022046439 cites W2168901628 @default.
• W2022046439 cites W2333499856 @default.
• W2022046439 cites W4211174180 @default.
• W2022046439 doi "https://doi.org/10.1089/cbr.2009.0714" @default.
• W2022046439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20187793" @default.
• W2022046439 hasPublicationYear "2010" @default.
• W2022046439 type Work @default.
• W2022046439 sameAs 2022046439 @default.
• W2022046439 citedByCount "27" @default.
• W2022046439 countsByYear W20220464392012 @default.
• W2022046439 countsByYear W20220464392013 @default.
• W2022046439 countsByYear W20220464392015 @default.
• W2022046439 countsByYear W20220464392016 @default.
• W2022046439 countsByYear W20220464392017 @default.
• W2022046439 countsByYear W20220464392018 @default.
• W2022046439 countsByYear W20220464392019 @default.
• W2022046439 countsByYear W20220464392020 @default.
• W2022046439 countsByYear W20220464392021 @default.
• W2022046439 countsByYear W20220464392022 @default.
• W2022046439 countsByYear W20220464392023 @default.
• W2022046439 crossrefType "journal-article" @default.
• W2022046439 hasAuthorship W2022046439A5000432967 @default.
• W2022046439 hasAuthorship W2022046439A5051036701 @default.
• W2022046439 hasAuthorship W2022046439A5063363406 @default.
• W2022046439 hasAuthorship W2022046439A5071965865 @default.
• W2022046439 hasAuthorship W2022046439A5080553382 @default.
• W2022046439 hasConcept C147483822 @default.
• W2022046439 hasConcept C147969180 @default.
• W2022046439 hasConcept C153911025 @default.
• W2022046439 hasConcept C154317977 @default.
• W2022046439 hasConcept C167672396 @default.
• W2022046439 hasConcept C17991360 @default.
• W2022046439 hasConcept C202751555 @default.
• W2022046439 hasConcept C203014093 @default.
• W2022046439 hasConcept C2776090121 @default.
• W2022046439 hasConcept C2776662205 @default.
• W2022046439 hasConcept C2777701055 @default.
• W2022046439 hasConcept C55493867 @default.
• W2022046439 hasConcept C86803240 @default.
• W2022046439 hasConcept C8891405 @default.
• W2022046439 hasConceptScore W2022046439C147483822 @default.
• W2022046439 hasConceptScore W2022046439C147969180 @default.
• W2022046439 hasConceptScore W2022046439C153911025 @default.
• W2022046439 hasConceptScore W2022046439C154317977 @default.
• W2022046439 hasConceptScore W2022046439C167672396 @default.
• W2022046439 hasConceptScore W2022046439C17991360 @default.
• W2022046439 hasConceptScore W2022046439C202751555 @default.
• W2022046439 hasConceptScore W2022046439C203014093 @default.
• W2022046439 hasConceptScore W2022046439C2776090121 @default.
• W2022046439 hasConceptScore W2022046439C2776662205 @default.
• W2022046439 hasConceptScore W2022046439C2777701055 @default.
• W2022046439 hasConceptScore W2022046439C55493867 @default.

• next